Spotlight on the public
On 17 October 2006, in the CALSYN vs/ GALZIN case, the European Court of First Instance (ECFI) confirmed that when assessing the risk of confusion between two pharmaceuticals trademarks the relevant public was composed of medical professionals and patients. Though the level of public attention is high, the very high similarity between the signs and …